TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31769240
Drug: Basal Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal Insulin
Study: 17070446
Drug: Basal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal and Prandial Insulin
Study: 9200390
Drug: Streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase with subcutaneously administered heparin
Study: 9200390
Drug: Streptokinase with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase with intravenously administered heparin
Study: 1410141
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg daily for 8 weeks, followed by 4 weeks of continuation)
Study: 3933455
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution containing 15.6% branched-chain amino acids
Study: 17192685
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (control)
Study: 30829275
Drug: Games and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Games and story therapy along with motivational intervention (Group B)
Study: 11897925
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg telmisartan + 12.5 mg HCTZ
Study: 17009837
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg telmisartan
Study: 10360855
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (10% arginine hydrochloride, 30 g over 15 min)
Study: 21145848
Drug: Danoprevir 200
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 200 mg q12 h
Study: 21145848
Drug: Danoprevir 300
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 300 mg q12 h (non-responders)
Study: 19441869
Drug: Ceftaroline 600
Normalized name: ceftaroline 600 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline 600 mg every 12 hours for 5-14 days
Study: 24421289
Drug: Alcohol infusion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusion (target BrAC = 0.06 g/dl)
Study: 21915733
Drug: Cefotetan disodium
Normalized name: Cefotetan Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan disodium 1.0 g
Study: 12113323
Drug: Human synthetic
Normalized name: Calcitonin, human synthetic
DrugBank: Human calcitonin (DB06773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human synthetic secretin, mean dose 3.4 clinical units, administered intravenously every 4th week, on three occasions.
Study: 7788039
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg daily (divided into two doses) for 12 months
Study: 1971701
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg ipsapirone (IPS)
Study: 3896659
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg)
Study: 25637151
Drug: Benson's relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Study: 12097666
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (500 mL twice daily)
Study: 31017851
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment for target morpheme
Study: 31017851
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment for target morpheme
Study: 25406730
Drug: Albiglutide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (30 mg/week)
Study: 21255780
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day)
Study: 16838651
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IFNalpha therapy (HDI)
Study: 16838651
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IFNalpha therapy (LDI)
Study: 16838651
Drug: IFNbeta in
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta in combination with chemotherapy
Study: 16838651
Drug: IFNbeta gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IFNbeta gene therapy
Study: 11872106
Drug: Myofascial trigger-point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial trigger-point massage therapy
Study: 10094253
Drug: Continued therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued therapy with barbiturates, phenytoin, and valproate
Study: 9345394
Drug: Rebif (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif (recombinant human interferon beta) administered subcutaneously at a dose of 8 million international units (MIU) once a week for 2 years
Study: 7430545
Drug: Indomethacin collyrium
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin collyrium administered prior to surgery
Study: 28007620
Drug: O2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2 group (received oxygen at 3 L/min via nasal prongs for three postoperative nights)
Study: 9755260
Drug: No cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cooling (control group; rectal temperature = 37.0 +/- 0.2 degreesC, n = 10)
Study: 9755260
Drug: Minimal systemic
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal systemic cooling (rectal temperature = 36.3 +/- 0.2 degreesC, n = 6)
Study: 9755260
Drug: Mild systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild systemic cooling (rectal temperature = 35.7 +/- 0.2 degreesC, n = 6)
Study: 31095995
Drug: KET/FENT (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: KET/FENT (three 25 μg fentanyl injections over 1.5 h)
Study: 31095995
Drug: Ketamine only
Normalized name: Ketamine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine only administration
Study: 29438092
Drug: Parsatuzumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Study: 29438092
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel
Study: 22410113
Drug: Enamel contralateral-antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel contralateral-antagonist
Study: 16305584
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg salbutamol (1 dose)
Study: 16305584
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg salbutamol (2 doses)
Study: 16305584
Drug: SLOW inhalation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLOW inhalation (20 l min(‐1))
Study: 16305584
Drug: FAST inhalation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAST inhalation (60 l min(‐1))
Study: 16305584
Drug: LATE inhalation
Normalized name: glycopyrrolate Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: LATE inhalation (slow inhalation after 5 s)
Study: 12079631
Drug: 1.45 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.45 microm diode laser with cryogen spray cooling, average power 12 W, treated on three separate occasions 3 weeks apart.
Study: 12079631
Drug: Cryogen spray
Normalized name: carbogen
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cryogen spray cooling alone, treated on the contralateral sides as control.
Study: 10442547
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 400 microg twice daily for 12 weeks
Study: 10442547
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 400 microg once daily for 12 weeks
Study: 10442547
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 400 microg once daily for a further 12 weeks
Study: 7778170
Drug: ATG (ATGAM)
Normalized name: ATGAM
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (ATGAM) administered in variable doses to maintain the absolute number of peripheral CD3 T cells at 50-100/microliters (Group 1)
Study: 7778170
Drug: ATG given
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG given at a fixed dose of 15 mg/kg/day (Group 2)
Study: 7778170
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (variable dosing) vs Group 2 (fixed dosing)
Study: 2088233
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg for 14 days)
Study: 30940694
Drug: Intramuscular nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nalmefene (1.5 mg)
Study: 21570643
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg
Study: 21036355
Drug: Atorvastatin in
Normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin in low cholesterol synthesisers with high absorption
Study: 17337382
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment using HDAC inhibitors and PPARγ agonists
Study: 17337382
Drug: PPARγ agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPARγ agonists (thiazolidinediones)
Study: 10937517
Drug: Thalidomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (150 mg orally at bedtime)
Study: 2869616
Drug: Oxprenolol slow
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol slow release 160 mg b.i.d.
Study: 6373264
Drug: Oxprenolol slow
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol slow release 160 mg b.i.d. in patients <65 years
Study: 6373264
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in patients <65 years continuing medication
Study: 24989892
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (arm A)
Study: 8683682
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin (BCG) instillation (120 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Study: 8683682
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C instillation (40 mg, weekly for 6 weeks, then monthly for up to 1 year and every 3 months during year 2)
Study: 27040557
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) targeting social skills and anxiety
Study: 21315879
Drug: One-session computer-based
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session computer-based exposure (CBE) treatment; 27-minute session with nine fear-eliciting spider pictures
Study: 16930908
Drug: Formulation optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation optimization
Study: 11549629
Drug: Transdermal dihydrotestosterone
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal dihydrotestosterone gel (70 mg daily)
Study: 7785133
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment (10% dibunol liniment and 5% ascorbic acid) injected 2 times a day, combined with 500,000 U of ampicillin for purulent sinusitis; injected once a day without antibiotic for catarrhal sinusitis.
Study: 7785133
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (4 ml dioxidine in a single dose for catarrhal sinusitis; 500,000 U ampicillin plus hydrocortisone emulsion 2 times a day for purulent sinusitis).
Study: 3136831
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg and 100 mg doses
Study: 24035110
Drug: Topical doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical doxycycline hyclate
Study: 19617207
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG (200 IU/l daily)
Study: 19617207
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with rFSH (Puregon) plus a GnRH‐antagonist
Study: 1856908
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg)
Study: 19850691
Drug: MMI+IID (Methimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMI+IID (Methimazole combined with intrathyroid injection of dexamethasone)
Study: 17304779
Drug: Ondansetron, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron, 4 mg intravenously (Control)
Study: 17304779
Drug: Inhaled isopropyl
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isopropyl alcohol (IPA)
Study: 15066931
Drug: +ISO (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: +ISO (soy protein drink providing 83 mg/day isoflavones)
Study: 11755456
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day ethyl eicosapentaenoate (E‐E)
Study: 11755456
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day ethyl eicosapentaenoate (E‐E)
Study: 8672379
Drug: Transdermal hyoscine
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hyoscine
Study: 27265390
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GL)
Study: 23278837
Drug: Oscillating Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating Pressure Infusion (OPI) method
Study: 21627685
Drug: Grade 1
Normalized name: SZOSIL Medical-Grade 15-Day Silicone Gel Sheet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 1 hypoglycaemia (blood glucose < 4 mmol/l with no associated symptoms)
Study: 19085723
Drug: Fluvoxamine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-150 mg)
Study: 11123495
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg testosterone enanthanate, intramuscularly every 2 weeks)
Study: 10968046
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of Augmentin intravenously
Study: 31610337
Drug: Beclomethasone suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone suppositories (3mg, n=42)
Study: 25038357
Drug: tesamorelin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin, 2 mg, subcutaneously daily for 6 months
Study: 23233650
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg lapatinib for 28-42 days before surgery
Study: 2887941
Drug: captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 25 mg twice daily
Study: 2887941
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg once daily
Study: 2887941
Drug: pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 10 mg twice daily
Study: 18377400
Drug: Midazolam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (10 mg increments, i.m. or i.v., at 10 min intervals, up to four doses)
Study: 12719802
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (0.5 mg/ml) perfusion before implantation
Study: 12719802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Euro-Collins solution without AA)
Study: 10362452
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium pyruvate (60%) and creatine (40%) (Group COM, n = 11)
Study: 2126394
Drug: NORPLANT six
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NORPLANT six capsule system
Study: 25431052
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg and 8 mg
Study: 28376282
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (RT)
Study: 18778905
Drug: Oxygen-ozone combined
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-ozone combined with collagenase injection
Study: 16917950
Drug: methylphenidate (OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (OROS and immediate release preparations)
Study: 1676367
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg)
Study: 3327150
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of cotrimoxazole
Study: 12890370
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LRS), equal to three times the EBL
Study: 12890370
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (HES) solution, equal to estimated blood loss (EBL)
Study: 10523748
Drug: Beta-carotene arm
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene arm (treatment)
Study: 1764952
Drug: Ofloxacin tablet
Normalized name: Ofloxacin Tablets
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin tablet (200 mg)
Study: 1764952
Drug: Ofloxacin tablet
Normalized name: Ofloxacin Tablets
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin tablet (300 mg)
Study: 30063901
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (0.9% saline)
Study: 30063901
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate injection
Study: 17312208
Drug: Sugammadex 8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 8.0 mg/kg
Study: 25923435
Drug: Sugammadex 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4.0 mg/kg
Study: 19933538
Drug: Sugammadex (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (various doses)
Study: 27756322
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral elemental diet (Elental®, 300 kcal/day)
Study: 16152823
Drug: Fuzheng Jiangnian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Jiangnian Capsule (FZJN)
Study: 16152823
Drug: Compound Salviae
Normalized name: Salvia sclarea seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Salviae droplet pill (CSDP)
Study: 31914451
Drug: Aspirin (ASP)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASP)
Study: 8993243
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) KIU or 280 mg in the pump)
Study: 31142943
Drug: 1% Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Vitamin K cream
Study: 31142943
Drug: 1% phenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% phenytoin cream
Study: 9756781
Drug: Pleconaril oral
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril oral solution (200 mg) coadministered with a standard English breakfast
Study: 9756781
Drug: Pleconaril oral
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril oral solution (200 mg) in fasting state
Study: 9756781
Drug: Pleconaril oral
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril oral solution (200 mg)
Study: 3278595
Drug: Pure alcohol
Normalized name: ISOPROPYL ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Biopure alcohol prep pads 70 isopropyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure alcohol injection
Study: 31049139
Drug: Cordyceps militaris
Normalized name: CORDYCEPS MILITARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cordyceps militaris (COG, 100 mg daily)
Study: 25350981
Drug: Droxidopa (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (100-600 mg, 3× daily)
Study: 21602542
Drug: Fluctuations in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluctuations in twice‐daily peak expiratory flow (PEF) over 6 months
Study: 18581891
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of salmon calcitonin (50 U) three times a week for 18 months
Study: 18581891
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 18 months (Control)